Search

everythinglearnresearchcommunity

for

Search:↓

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.

Hair loss treatments Cosmerna, RU, and Pyri discussed. Cosmerna inhibits androgen receptors, but not 100%, so RU/Pyri can be used synergistically.

A 22-year-old male has been using finasteride for 4 months without major side effects but is concerned about hormone test results showing low SHBG and high estrogen. He plans to consult a doctor and is considering alternatives like minoxidil or topical finasteride to avoid health issues.

The user reduced serum DHT by 60% using Advanced Trichology's natural DHT blocker but saw no improvement in hair loss. They are considering switching to finasteride due to its proven effectiveness in inhibiting scalp DHT.

A 31-year-old male experienced hair shedding after rapid weight loss and stopping vitamins, despite using minoxidil and other supplements. He is considering Saw Palmetto and Pumpkin Seed Oil instead of finasteride due to trying for kids, and is concerned about high ferritin and DHEAS levels.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

The user is experiencing stage 2 hair loss and thinning, noticing more scalp visibility with short hair. They are considering diet, yoga, scalp massage, supplements, and a serum recommended by their doctor, and questioning if it's safe to stop using the serum and whether to get a blood test since hair loss isn't a family trait.

The user started using finasteride, minoxidil, and biotin for male pattern baldness (MPB) and is experiencing rapid thinning. They are questioning if low blood flow to the head could be contributing to their hair loss.

Using Pyrilutamide or RU as monotherapy for hair loss? Share experiences.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The user is concerned about patchy hair regrowth after 5.5 months of treatment. They are questioning if more hair growth can be expected in the upcoming months.

The user has tried various treatments for hair loss, including finasteride, dutasteride, RU58841, Pyrilutamide, and several topical growth factors, but continues to experience a receding hairline and thinning. Despite maintaining a healthy lifestyle, the user is unsure why these treatments are ineffective and seeks advice on the underlying cause.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

The user started balding at 16/17 and tried various treatments including minoxidil, finasteride, and dutasteride with little success. They recently started applying diclofenac gel to their bald areas and noticed some hair regrowth, attributing this to diclofenac's ability to lower prolactin levels and its anti-inflammatory effects.

DHT, not testosterone, causes hair loss. Treatments like finasteride, dutasteride, and RU58841 target DHT to manage hair loss.

A 48-year-old male is experiencing hair loss despite taking finasteride for four months. He is considering oral minoxidil but is concerned about high blood pressure and is unsure about taking spironolactone.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

The user is treating androgenetic alopecia with finasteride and discovered a folic acid deficiency. They are asking if curing the deficiency can worsen or improve their hair condition.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Using 0.1% Alfatradiol and 1% Pyrilutamide stopped hair loss, reducing shedding from over 150 hairs a day to less than 10, with no side effects. The user also uses Minoxidil and microneedling, applying the treatments twice daily.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.